Latest news with #Rs34.7
Express Tribune
9 hours ago
- Business
- Express Tribune
KE base tariff raised by Rs6.15 per unit
Prior approval to NEPRA K-electric consumer may seen a huge relief over electricity bills. PHOTO: FILE In a bold assertion of its regulatory autonomy, Pakistan's power watchdog has notified K-Electric's long-delayed multi-year tariffs for supply, distribution, and transmission through 2030 — despite an unresolved review motion by the federal government. The power regulator has notified Rs6.15 per unit increase in base tariff for KE consumers. The government implements uniform across the country and government provides subsidy for KE consumers to implement uniform tariff. The National Electric Power Regulatory Authority (Nepra) moved ahead with the notification after determining that no legal bar existed to halt implementation. It invoked its enhanced powers under a 2021 legal amendment, which allows the regulator to issue tariff notifications directly — authority that previously rested with the federal government. The landmark move reflects pressure from international lenders, notably the IMF and the World Bank, to depoliticize tariff-setting and fast-track power sector reforms. "This situation could impair KE's financial health and undermine power supply continuity, ultimately affecting consumers and the broader energy market," Nepra warned in its statement. The newly notified average power supply tariff for KE stands at Rs 39.97 per kilowatt-hour for 2023-24, comprising Rs 31.96/kWh in power purchase cost, Rs 2.86 for transmission, Rs 3.31 for distribution, and Rs 2.28 as the supply margin. A prior year adjustment of minus Rs 0.44/kWh has also been included. Nepra estimated KE's total revenue requirement for FY 2023-24 at Rs 606.9 billion, with Rs34.7 billion allocated for supply margin and Rs 36.2 billion set aside to cover recovery losses. Despite the formal tariff approval, KE's finances remain under severe pressure. With bill recovery slipping to 91.5pc in FY 2023-24 and projected to fall to 90.5pc next year, the utility could face cumulative under-recoveries nearing Rs97 billion over two fiscal years. Nepra cautioned that KE's permitted Rs21.6 billion return on distribution operations might be wiped out without government support or adjustments. Nepra simultaneously approved a distribution tariff of Rs 3.31/kWh and Rs 2.684/kWh specifically to support a Rs 43.4 billion investment plan over the seven-year Multi-Year Tariff period. The government had challenged K-Electric's multi-year tariff (2024-30) approved by the power regulator last week, alleging the utility got an undue favour of Rs750 billion over the seven-year period at the cost of the national exchequer, power consumers across the country and taxpayers at large. In a statement, the power division had announced that the six tariff interventions allowed by Nepra to KE entailed a financial impact of Rs453bn spread over seven years. On top of that, the division added, a fuel cost impact higher than the national average for 2024-25 alone meant an additional cost of Rs41bn, which even if it remains flat would translate into Rs287bn in seven years. The division said the government position was to seek review of the Nepra determination to ensure fairness and uniformity, tariff must reflect actual costs and reasonable returns to protect consumers and there should be no extra allowance for inefficiency.
Time of India
10-07-2025
- Health
- Time of India
Speed up work on GMCs in Washim, Bhandara, Ambernath, Palghar: Fadnavis
Nagpur: Chief minister Devendra Fadnavis has directed all departments to coordinate and prioritise making land available for the construction of proposed govt medical colleges (GMCHs) at Washim, Bhandara, Ambernath, and Palghar. He spoke at a review meeting held at Vidhan Bhavan to assess the progress of land availability and construction for these medical colleges and hospitals on Wednesday. Deputy chief minister Ajit Pawar, medical education minister Hasan Mushrif, food and civil supplies minister Chhagan Bhujbal, health minister Prakash Abitkar, minister of state Meghana Bordikar, and chief secretary Rajesh Kumar were present. Fadnavis said that the govt had approved the construction of new medical colleges in Washim, Bhandara, Ambernath, and Palghar. He instructed local representatives and district administrations to inspect and finalise suitable land for these projects. He emphasised the need for time-bound planning, including the appointment of consultant agencies and the completion of related tasks, to avoid delays. Local administrations were directed to ensure no work is delayed. Fadnavis further noted that GMCHs with a capacity of 100 students and hospitals with 430 beds are under construction in Sindhudurg, Jalna, Amravati, Washim, Wardha, Buldhana, Gadchiroli, Parbhani, and Hingoli. Additional funding is required to provide facilities at these colleges. He directed the PWD to prepare a revised comprehensive proposal for all works, in accordance with the National Medical Commission's regulations, and present it to the high-level committee. In October 2024, Prime Minister Narendra Modi virtually inaugurated two new GMCs in Bhandara and Washim, Maharashtra, each offering 100 MBBS seats for the 2024–25 academic year. Affiliated with Maharashtra University of Health Sciences (MUHS), both colleges received National Medical Commission approval. Bhandara's GMC will operate on a 25-acre campus at Paladi village, while Washim will utilise the district hospital. Each has 448 sanctioned posts, with 197 to be filled this year, supported by Rs34.7 crore in funding. Plans for 400–450-bed hospitals are set for completion within 2–3 years. BOX Fadnavis urges online expansion of health services Chief minister Devendra Fadnavis directed guardian secretaries to devise planned programmes for urban health projects, emphasising the online delivery of public health department services via the Aaple Sarkar portal. Speaking at a Vidhan Bhavan review meeting, Fadnavis stressed strengthening primary health centres, estimating Rs5,983 crore for modernising 398 centres and 2,806 sub-centres. He called for effective implementation of health schemes, simplified procurement, and AI integration. Fadnavis also urged for updation of the department's website, decentralising services, and drafting a state health policy.
Time of India
21-05-2025
- Business
- Time of India
Sun Pharma Q4 Preview: PAT may grow 6% YoY; domestic business to drive revenue
Pharma major Sun Pharma is likely to see high single-digit growth in its bottom line in the fourth quarter on the back of continued outperformance in the domestic business. According to an average estimate of five brokerages, revenue is expected to grow 9% year-on-year (YoY). Meanwhile, net profit for the reporting quarter will lag the revenue as an average of five estimates showed 6% YoY growth. Analysts are building in $500 million US sales in 4QFY25, primarily due to higher gRevlimid sales. Meanwhile, gross margins are seen declining 30 bps QoQ to 79.7% due to lower milestone income. For the specialty business, there is 20% YoY growth expectation at $325 million for 4Q owing to steady execution. Here's what brokerages expect from Sun Pharma's Q4 Kotak Equities We expect Sun Pharma's 4QFY25 overall sales to grow 8% YoY. For the global specialty business, we bake in a 17% QoQ sales decline to $308 million in 4QFY25, as specialty sales in 3QFY25 had inventory buildout and seasonality benefit. We build in a 9% YoY growth in India and a 9% YoY growth in RoW/EMs for 4QFY25. We expect Sun Pharma's 4QFY25 gross margins to decline 30 bps QoQ to 79.7% due to lower milestone income. We bake in R&D spends at 7.7% of sales in 4QFY25 (+150 bps QoQ). On the EBITDA front, we factor in a 12% YoY growth to Rs34.7 bn, with an EBITDA margin decline of 390 bps QoQ to 26.8% due to higher R&D spend. Motilal Oswal Expect DF sales to grow 13% YoY for the quarter. Clarity on the launch of Deuruxolitinib in the US market and watch out for the launch in other global markets. Factors to drive consistent growth in branded generics in emerging/ROW markets. Any further progress on products in Amplitude basket. YES Securities Revenue decline seen as Q3 had one-off milestone income in ROW markets coupled with sequential fall in domestic business. US to inch up 2% QoQ on likely better Taro numbers (based on historical pattern). Higher R&D vs Q3 to dampen margin QoQ. Nuvama We build Sun Pharma's revenue to grow by 9% YoY as domestic business continues its outperformance at 10%. We build US revenue at $503 million and global specialty business at $335 million, with dermatology product sales seeing improvement. R&D spend is expected to be at 6.4% of the sales. We estimate EBITDA/PAT to grow by 22%/4% YoY with EBITDA margins at 28.4% for Q4FY25. ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)
Economic Times
21-05-2025
- Business
- Economic Times
Sun Pharma Q4 Preview: PAT may grow 6% YoY; domestic business to drive revenue
Pharma major Sun Pharma is likely to see high single-digit growth in its bottom line in the fourth quarter on the back of continued outperformance in the domestic business. According to an average estimate of five brokerages, revenue is expected to grow 9% year-on-year (YoY). ADVERTISEMENT Meanwhile, net profit for the reporting quarter will lag the revenue as an average of five estimates showed 6% YoY growth. Analysts are building in $500 million US sales in 4QFY25, primarily due to higher gRevlimid sales. Meanwhile, gross margins are seen declining 30 bps QoQ to 79.7% due to lower milestone income. For the specialty business, there is 20% YoY growth expectation at $325 million for 4Q owing to steady execution. We expect Sun Pharma's 4QFY25 overall sales to grow 8% YoY. For the global specialty business, we bake in a 17% QoQ sales decline to $308 million in 4QFY25, as specialty sales in 3QFY25 had inventory buildout and seasonality benefit. We build in a 9% YoY growth in India and a 9% YoY growth in RoW/EMs for 4QFY25. ADVERTISEMENT We expect Sun Pharma's 4QFY25 gross margins to decline 30 bps QoQ to 79.7% due to lower milestone income. We bake in R&D spends at 7.7% of sales in 4QFY25 (+150 bps QoQ). On the EBITDA front, we factor in a 12% YoY growth to Rs34.7 bn, with an EBITDA margin decline of 390 bps QoQ to 26.8% due to higher R&D spend. ADVERTISEMENT Expect DF sales to grow 13% YoY for the quarter. Clarity on the launch of Deuruxolitinib in the US market and watch out for the launch in other global markets. Factors to drive consistent growth in branded generics in emerging/ROW markets. Any further progress on products in Amplitude decline seen as Q3 had one-off milestone income in ROW markets coupled with sequential fall in domestic business. US to inch up 2% QoQ on likely better Taro numbers (based on historical pattern). Higher R&D vs Q3 to dampen margin QoQ. ADVERTISEMENT NuvamaWe build Sun Pharma's revenue to grow by 9% YoY as domestic business continues its outperformance at 10%. We build US revenue at $503 million and global specialty business at $335 million, with dermatology product sales seeing improvement. R&D spend is expected to be at 6.4% of the sales. We estimate EBITDA/PAT to grow by 22%/4% YoY with EBITDA margins at 28.4% for Q4FY25. ADVERTISEMENT (Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times) (You can now subscribe to our ETMarkets WhatsApp channel)
